Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome
- ER-Kim Gains Exclusive Rights to Commercialize QRX003 Across Central & Eastern Europe - Fifth Distribution Partnership Established Since Quoin’s...